These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 34697141)

  • 21. Combination of CDK4/6 and mTOR Inhibitors Suppressed Doxorubicin-resistant Osteosarcoma in a Patient-derived Orthotopic Xenograft Mouse Model: A Translatable Strategy for Recalcitrant Disease.
    Oshiro H; Tome Y; Miyake K; Higuchi T; Sugisawa N; Kanaya F; Nishida K; Hoffman RM
    Anticancer Res; 2021 Jul; 41(7):3287-3292. PubMed ID: 34230123
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Eribulin Regresses a Doxorubicin-resistant Dedifferentiated Liposarcoma in a Patient-derived Orthotopic Xenograft Mouse Model.
    Igarashi K; Kawaguchi K; Kiyuna T; Miyake K; Higuchi T; Yamamoto N; Hayashi K; Kimura H; Miwa S; Singh SR; Tsuchiya H; Hoffman RM
    Cancer Genomics Proteomics; 2020; 17(4):351-358. PubMed ID: 32576580
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sorafenib and Palbociclib Combination Regresses a Cisplatinum-resistant Osteosarcoma in a PDOX Mouse Model.
    Higuchi T; Sugisawa N; Miyake K; Oshiro H; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Chawla SP; Bouvet M; Singh SR; Tsuchiya H; Hoffman RM
    Anticancer Res; 2019 Aug; 39(8):4079-4084. PubMed ID: 31366491
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Temozolomide combined with irinotecan regresses a cisplatinum-resistant relapsed osteosarcoma in a patient-derived orthotopic xenograft (PDOX) precision-oncology mouse model.
    Igarashi K; Kawaguchi K; Kiyuna T; Miyake K; Miyake M; Li Y; Nelson SD; Dry SM; Singh AS; Elliott IA; Russell TA; Eckardt MA; Yamamoto N; Hayashi K; Kimura H; Miwa S; Tsuchiya H; Eilber FC; Hoffman RM
    Oncotarget; 2018 Jan; 9(8):7774-7781. PubMed ID: 29487690
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Osteosarcoma Patient-derived Orthotopic Xenograft (PDOX) Models Used to Identify Novel and Effective Therapeutics: A Review.
    Higuchi T; Igarashi K; Yamamoto N; Hayashi K; Kimura H; Miwa S; Bouvet M; Tsuchiya H; Hoffman RM
    Anticancer Res; 2021 Dec; 41(12):5865-5871. PubMed ID: 34848441
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The combination of oral-recombinant methioninase and azacitidine arrests a chemotherapy-resistant osteosarcoma patient-derived orthotopic xenograft mouse model.
    Higuchi T; Sugisawa N; Yamamoto J; Oshiro H; Han Q; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Tan Y; Kuchipudi S; Bouvet M; Singh SR; Tsuchiya H; Hoffman RM
    Cancer Chemother Pharmacol; 2020 Feb; 85(2):285-291. PubMed ID: 31705268
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A patient-derived orthotopic xenograft (PDOX) mouse model of a cisplatinum-resistant osteosarcoma lung metastasis that was sensitive to temozolomide and trabectedin: implications for precision oncology.
    Igarashi K; Murakami T; Kawaguchi K; Kiyuna T; Miyake K; Zhang Y; Nelson SD; Dry SM; Li Y; Yanagawa J; Russell TA; Singh AS; Tsuchiya H; Elliott I; Eilber FC; Hoffman RM
    Oncotarget; 2017 Sep; 8(37):62111-62119. PubMed ID: 28977930
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of Oral Recombinant Methioninase and Eribulin on a PDOX Model of Triple-negative Breast Cancer (TNBC) Liver Metastasis.
    Lim HI; Sun YU; Han Q; Yamamoto J; Hoffman RM
    In Vivo; 2021; 35(5):2531-2534. PubMed ID: 34410939
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multikinase-Inhibitor Screening in Drug-resistant Osteosarcoma Patient-derived Orthotopic Xenograft Mouse Models Identifies the Clinical Potential of Regorafenib.
    Higuchi T; Igarashi K; Yamamoto N; Hayashi K; Kimura H; Miwa S; Bouvet M; Tsuchiya H; Hoffman RM
    Cancer Genomics Proteomics; 2021; 18(5):637-643. PubMed ID: 34479916
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effective Metabolic Targeting of Human Osteosarcoma Cells
    Igarashi K; Kawaguchi K; Kiyuna T; Miyake K; Murakami T; Yamamoto N; Hayashi K; Kimura H; Miwa S; Tsuchiya H; Hoffman RM
    Anticancer Res; 2017 Sep; 37(9):4807-4812. PubMed ID: 28870899
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Case of Rare Matrix-producing Triple-negative Breast Carcinoma for Which Drug Response in a Patient-derived Orthotopic Xenograft Mouse Model Was Correlated With Patient Response.
    Nomura T; Kurebayashi J; Moriya T; Saito W; Murata T; Yamamoto J; Hozumi C; Hoffman RM
    Anticancer Res; 2021 Dec; 41(12):6191-6197. PubMed ID: 34848473
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An mTOR and VEGFR inhibitor combination arrests a doxorubicin resistant lung metastatic osteosarcoma in a PDOX mouse model.
    Oshiro H; Tome Y; Miyake K; Higuchi T; Sugisawa N; Kanaya F; Nishida K; Hoffman RM
    Sci Rep; 2021 Apr; 11(1):8583. PubMed ID: 33883561
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High Efficacy of Pazopanib on an Undifferentiated Spindle-Cell Sarcoma Resistant to First-Line Therapy Is Identified With a Patient-Derived Orthotopic Xenograft (PDOX) Nude Mouse Model.
    Igarashi K; Kawaguchi K; Murakami T; Kiyuna T; Miyake K; Singh AS; Nelson SD; Dry SM; Li Y; Yamamoto N; Hayashi K; Kimura H; Miwa S; Tsuchiya H; Eilber FC; Hoffman RM
    J Cell Biochem; 2017 Sep; 118(9):2739-2743. PubMed ID: 28176365
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oral recombinant methioninase combined with paclitaxel arrests recalcitrant ovarian clear cell carcinoma growth in a patient-derived orthotopic xenograft (PDOX) nude-mouse model.
    Sugisawa N; Higuchi T; Han Q; Hozumi C; Yamamoto J; Tashiro Y; Nishino H; Kawaguchi K; Bouvet M; Murata T; Unno M; Hoffman RM
    Cancer Chemother Pharmacol; 2021 Jul; 88(1):61-67. PubMed ID: 33768300
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Combination of Olaratumab with Doxorubicin and Cisplatinum Regresses a Chemotherapy-Resistant Osteosarcoma in a Patient-Derived Orthotopic Xenograft Mouse Model.
    Higuchi T; Sugisawa N; Miyake K; Oshiro H; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Bouvet M; Singh SR; Tsuchiya H; Hoffman RM
    Transl Oncol; 2019 Sep; 12(9):1257-1263. PubMed ID: 31299622
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Novel Procedure for Orthotopic Tibia Implantation for Establishment of a More Clinical Osteosarcoma PDOX Mouse Model.
    Wu NF; Yamamoto J; Bouvet M; Hoffman RM
    In Vivo; 2021; 35(1):105-109. PubMed ID: 33402455
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combination Treatment With Sorafenib and Everolimus Regresses a Doxorubicin-resistant Osteosarcoma in a PDOX Mouse Model.
    Higuchi T; Sugisawa N; Miyake K; Oshiro H; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Kline Z; Belt P; Chawla SP; Bouvet M; Singh SR; Tsuchiya H; Hoffman RM
    Anticancer Res; 2019 Sep; 39(9):4781-4786. PubMed ID: 31519579
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Regorafenib regressed a doxorubicin-resistant Ewing's sarcoma in a patient-derived orthotopic xenograft (PDOX) nude mouse model.
    Miyake K; Kiyuna T; Kawaguchi K; Higuchi T; Oshiro H; Zhang Z; Wangsiricharoen S; Razmjooei S; Li Y; Nelson SD; Murakami T; Hiroshima Y; Matsuyama R; Bouvet M; Chawla SP; Singh SR; Endo I; Hoffman RM
    Cancer Chemother Pharmacol; 2019 May; 83(5):809-815. PubMed ID: 30758647
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Temozolomide targets and arrests a doxorubicin-resistant follicular dendritic-cell sarcoma patient-derived orthotopic xenograft mouse model.
    Oshiro H; Tome Y; Kiyuna T; Miyake K; Kawaguchi K; Higuchi T; Miyake M; Zang Z; Razmjooei S; Barangi M; Wangsiricharoen S; Nelson SD; Li Y; Bouvet M; Singh SR; Kanaya F; Hoffman RM
    Tissue Cell; 2019 Jun; 58():17-23. PubMed ID: 31133242
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High Clinical Concordance of Drug Resistance in Patient-derived Orthotopic Xenograft (PDOX) Mouse Models: First Step to Validated Precise Individualized Cancer Chemotherapy.
    Higuchi T; Yamamoto N; Hayashi K; Miwa S; Igarashi K; Tsuchiya H; Hoffman RM
    Anticancer Res; 2023 Oct; 43(10):4277-4284. PubMed ID: 37772554
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.